<DOC>
	<DOCNO>NCT02945774</DOCNO>
	<brief_summary>Neuroinflammation increasingly implicate potential critical pathogenic mechanism variety neurologic psychiatric disorder . This study use hybrid PET/MRI image evaluate neuroinflammation relationship cerebral perfusion frontotemporal dementia ( FTD ) . Patients FTD recruit Cognitive Neurology Aging Brain clinic Parkwood Institute undergo neurocognitive assessment MRI/PET use PET ligand FEPPA bind activated microglia , marker neuroinflammation . Correlations conduct determine whether abnormal neuroinflammation present Frontotemporal dementia whether differential pattern neuroinflammation present different FTD clinical molecular subtypes , determine relationship neuroinflammation , cerebral perfusion use arterial spin label MRI image technique , index brain structure include volumetric white matter analysis .</brief_summary>
	<brief_title>Molecular Neuroimaging Neuroinflammation Neurodegenerative Dementias</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Frontotemporal Dementia</mesh_term>
	<mesh_term>Aphasia , Primary Progressive</mesh_term>
	<mesh_term>Pick Disease Brain</mesh_term>
	<criteria>1 . Patients diagnose probable Frontotemporal Dementia neurologically healthy control participant history neurological problem 2 . Study partner available frequent contact subject accompany subject clinic visit duration protocol . 3 . Visual auditory acuity adequate neuropsychological test 4 . Good general health disease expect interfere study . 5 . Subject pregnant , lactating , childbearing potential ( i.e . woman must two year postmenopausal , surgically sterile practice effictive form family plan 6 . Willing participate longitudinal imaging study 12 month . 7 . Willing undergo MRI ( 3Tesla ) / PET scan ( FEPPA ligand ) medical contraindication MRI . 1 . Any significant neurologic disease suspect Frontotemporal Dementia would better account symptom ( i.e . frontal lobe stroke ) . 2 . Screening/baseline MRI scan evidence infection , infarction , focal lesion . Subjects multiple lacunes exclude . 3 . Presence pacemaker , aneurysm clip , artificial heart valve , ear implant , metal fragment foreign object eye , skin body may preclude MRI participation per MRI screen form . 4 . Major depression , bipolar disorder describe DSMIV within past 1 year . Psychotic feature , agitation behavioral problem within last 3 month could lead difficulty comply protocol . 5 . History schizophrenia ( DSM IV criterion ) . 6 . Any significant systemic illness unstable medical condition could lead difficulty comply protocol . 7 . Clinically significant abnormality B12 , thyroid function test might interfere study . 8 . Investigational agent prohibit one month prior entry duration trial . 9 . Exclusion FEPPA : Current recent participation procedure involve radioactive agent total radiation dose exposure subject give year would exceed limit annual total dose commitment set forth . The current regulation radiation dose patient volunteer health control volunteer contain within Health Canada 's recently amend ( June 19 , 2012 ) Regulations Amending Food Drug Regulations ( Positronemitting Radiopharmaceuticals ) . Limitations effective total body dose 50 mSv ( C.03.305 ( c ) ) increase previous value 20 mSv ( Table 1 INFO0491 ) . 10 . Exclusion Criteria control undergoing arterial line placement : Absent pulse , Thromboangiitis obliterans ( Buerger disease ) , Burns cannulation site , Inadequate circulation extremity , Raynaud syndrome , Anticoagulation therapy , Atherosclerosis upper extremity vessel , Coagulopathy , inadequate collateral flow , Infection cannulation site , Previous surgery area , Synthetic vascular graft .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>PET</keyword>
	<keyword>MRI</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Microglia</keyword>
	<keyword>FEPPA</keyword>
</DOC>